HOME >> BIOLOGY >> NEWS
From clinical cancer research: rethinking therapeutic cancer vaccine trials

Ongoing therapeutic cancer vaccine trials have yet to show evidence of vaccines spurring a patients immune system to shrink tumors -- yet patients who receive these vaccines in trials tend to live longer and respond better to subsequent treatment. In the July 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, a team of National Cancer Institute researchers asks a fundamental question: are we looking at cancer vaccine trials the wrong way"

In a review of five prostate cancer vaccine trials, NCI researchers offer evidence that patients who receive vaccines may respond better to subsequent chemotherapy or hormone treatment. The specific results or endpoints of these clinical trials, however, were not the long term survival of patients, but rather the degree to which the vaccine caused tumors to shrink. According to the researchers, since they didnt achieve their primary endpoints, these vaccines may be abandoned as dead-ends, despite their real therapeutic value in terms of prolonging patient survival.

Clinical data are providing evidence that patients are living longer following vaccination, de-spite the fact that trials do not show the vaccines can induce the immune system into shrinking tumors, said Jeffrey Schlom, Ph.D., chief of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute. The data suggests that the scientific community and regulatory committees ought to rethink the design of clinical vaccine trials and our current approach to measuring the effectiveness of a cancer vaccine.

According to the researchers, it may be more helpful to think of the effectiveness of a vaccine in terms of the response of the patient, rather than the response of the tumor. While the Response Criteria in Solid Tumors (RECIST) experimental standards works well in evaluating therapies that are toxic to tumors, such as radiation or chemotherapy, they are less capable of me
'"/>

Contact: Greg Lester
lester@aacr.org
267-646-0554
American Association for Cancer Research
3-Jul-2007


Page: 1 2

Related biology news :

1. Preclinical study links gene to brain aneurysm formation
2. Gene variant is associated with brain anatomy, clinical course of ADHD
3. New joint replacement material developed at MGH put to first clinical use
4. Serica scientists win AOSSM Award for ACL (knee) tissue regeneration in preclinical study
5. Manganese levels increase in scrapie-infected sheep before clinical symptoms develop
6. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
7. Alzheimers drug based on Purdue -- designed inhibitor begins clinical trials
8. UT Southwestern joins national clinical trial to uncover long-term effects of West Nile virus
9. BDSI announces positive phase III clinical trial results
10. Oncolytics Biotech Inc. proceeds to initiate US Phase II sarcoma clinical trial
11. NIH announces phase III clinical trial of creatine for Parkinsons disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):
(Date:10/9/2017)... (PRWEB) , ... October 09, 2017 , ... ... a four-tiered line of medical marijuana products targeting the needs of consumers who ... packaging of Kindred takes place in Phoenix, Arizona. , As operators of two ...
(Date:10/7/2017)... (PRWEB) , ... October 06, ... ... years’ experience providing advanced instruments and applications consulting for microscopy and surface ... expertise in application consulting, Nanoscience Analytical offers a broad range of contract ...
(Date:10/7/2017)... WALTHAM, Mass. , Oct. 6, 2017 /PRNewswire/ ... pioneering work of three scientists, Jacques Dubochet, ... whose breakthrough developments in cryo-electron microscopy ... this technology within the structural biology community. The ... Scientific. Scientists can now routinely produce highly resolved, ...
(Date:10/6/2017)... D.C. (PRWEB) , ... October 06, 2017 , ... ... will host a lunch discussion and webinar on INSIGhT, the first-ever adaptive clinical ... Principal Investigator, Dana-Farber Cancer Institute. The event is free and open to the ...
Breaking Biology Technology:
Cached News: